Wende Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wende Li has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Penghui Zhou
State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
46 shared publications - Xiaojun Xia
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
44 shared publications - Danyang Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
42 shared publications - Jianeng Zhang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
42 shared publications - Liping Xu
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
42 shared publications - Shuangye Liao
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
42 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 5. The independent replicates of Figure 5H
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 5. The independent replicates of Figure 5H
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Tumor cells employ metabolic mechanisms to limit antitumor immunity and promote resistance to immunotherapy. However, how immunotherapy modulates tumor metabolism remains unclear. In this study, we demonstrated that anti–PD-1 treatment regulated cholesterol biosynthesis in cancer cells through the effector cytokine IFNγ. Mechanistically, IFNγ-induced IRF1 transcriptionally suppresses the expression of SREBF2, a master regulator of cholesterol synthesis. Reduced cholesterol content inhibited tumor growth and sensitized tumor cells to statins, drugs that can lower cholesterol. Overall, our study reveals that IFNγ-mediated inhibition of cholesterol biosynthesis in tumor cells is an important antitumor mechanism of immunotherapy.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Tumor cells employ metabolic mechanisms to limit antitumor immunity and promote resistance to immunotherapy. However, how immunotherapy modulates tumor metabolism remains unclear. In this study, we demonstrated that anti–PD-1 treatment regulated cholesterol biosynthesis in cancer cells through the effector cytokine IFNγ. Mechanistically, IFNγ-induced IRF1 transcriptionally suppresses the expression of SREBF2, a master regulator of cholesterol synthesis. Reduced cholesterol content inhibited tumor growth and sensitized tumor cells to statins, drugs that can lower cholesterol. Overall, our study reveals that IFNγ-mediated inhibition of cholesterol biosynthesis in tumor cells is an important antitumor mechanism of immunotherapy.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 3. The independent replicates of Figure 2J
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 3. The independent replicates of Figure 2J
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Figure 1. The RNA-sequencing analysis for IFN-γ-treated B16 cells
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Figure 1. The RNA-sequencing analysis for IFN-γ-treated B16 cells
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 9. The public expression data of cholesterol biosynthesis genes in patients receiving anti-PD-1 treatment
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 9. The public expression data of cholesterol biosynthesis genes in patients receiving anti-PD-1 treatment
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 7. The independent replicates of Supplementary Figure 2K
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 7. The independent replicates of Supplementary Figure 2K
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 4. The independent replicates of Figure 3G
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 4. The independent replicates of Figure 3G
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 8. The RNA-sequencing data of B16 tumors with anti-PD-1 treatment
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 8. The RNA-sequencing data of B16 tumors with anti-PD-1 treatment
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 10. The RNA-sequencing data of IFN-γ-treated B16 cells
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 10. The RNA-sequencing data of IFN-γ-treated B16 cells
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 2. The independent replicates of Figure 1K
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis
Supplementary Table 2. The independent replicates of Figure 1K